Acenocoumarol is an oral anticoagulant of the coumarin series, synthesized and developed in the Geigy laboratoires in the late 1960s and sold in the United States under the brand name of Sintrom. It lowers the prothrombin level of the blood. It is a white crystalline powder without taste and odor and has a molecular weight of 353. It is soluble in alkaline solutions but only slightly soluble in water and organic solvents. Chemically, acenocoumarol is 3-(alpha-acetonyl-4-nitrobenzyl)-4-hydroxycoumarin.
Acenocoumarol is indicated in coronary thrombosis, arterial thrombotic occlusion, pulmonary embolism, thrombophlebitis, and auricular fibrillation with embolization. Anti-coagulant therapy is also indicated in cardiovascular surgery and selective cases of congestive heart failure.
The onset of hypoprothrombinemic effect is fairly rapid. The therapeutic degree of hypoprothrombinamia may be achieved within 36-48 hours.
Great caution should be observed in patients with impaired liver functions. It is contraindicated in hemorrhagic diathesis.